The HPV vaccine will protect girls from developing cervical cancer when they are adults. It is available free of charge from the HSE for all girls in 1st year of second level school.
The Health Service Executive (HSE) offers protection against HPV to reduce the chance of women developing cervical cancer by using the HPV vaccine. The vaccine is offered to all girls in their 1st year of second level schools. The vaccine is given through a school based programme, to ensure high vaccine uptake. However, in specific instances some girls will be invited to special HSE clinics for their vaccines.
Since September 2014
all girls less than 15 years of age will require two doses of HPV vaccine given at least six months apart.
The HSE will let you know the date they will attend your school and give the immunisations. If a student misses that immunisation in school, the HSE will arrange for the student to be vaccinated at a HSE clinic.
To read more about HPV please visit the following pages
The following information materials are available for parents of girls in First Year of second level schools or equivalent in special schools.
Information Booklet - English | Irish | Arabic | Simplified Chinese | German | French | Polish | Portuguese | Romanian | Russian
Consent Form - English and Irish combined form
Post Vaccination Advice - English | Irish
The vaccine used in the school programme is called Gardasil. It is manufactured by Sanofi Pasteur MSD. Please read Gardasil - Summary of Product Characteristics (SPC) and Gardasil - Patient Information Leaflet (PIL) for more information about the vaccine.
If you have any questions please contact the schools immunisation programme office in your area. The contact phone numbers are available in English and Irish.
More Information about HPV can be found at the following websites:
www.hpra.ie/homepage/medicines/special-topics/hpv-school-immunisation information about HPV vaccine and the HPV immunisation programme
www.hpsc.ie/A-Z/Hepatitis/HPV/ information about HPV
The following information materials are available for healthcare professionals who carry out the programme.
Gardasil - Summary of Product Characteristics (SPC)
Gardasil - Patient Information Leaflet (PIL)
Royal College of Physicians of Ireland - Immunisation Guidelines for Ireland. Chapter 10 - Human Papillomavirus
School Immunisation Programme Guidelines for Staff 2015/2016 - Version 5.4 (Updated 23rd February 2016)
HPV Frequently Asked Questions Version 12.2 (February 2016)
(Please note when you click on the SPC or PIL for Gardasil you will be leaving our website www.immunisation.ie)
Medication Protocol for the School Immunisation Programme
Gardasil Medication Protocol (February 2015)
Anaphylaxis Protocol (September 2015)
Change to the NIAC Guidelines for treatment of Anaphylaxis (November 2015)
Gardasil safety reports
The World Health Organization Global Advisory Committee for Vaccine Safety (GACVS) has reviewed the evidence on the safety of Gardasil vaccine. WHO concluded in December 2015 that Gardasil continues to have an excellent safety profile. Further information can be found here
In November 2015 the European Medicines Agency (EMA) reported on a review of HPV vaccines. This report found no evidence the vaccine was linked to chronic fatigue like conditions. Please see link for full details http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500196773.pd
Stillo M, Santisteve P & Lopalco P. ECDC (2015). Safety of human papillomavirus vaccines: a review, Expert Opin. Drug Saf. 14(5) P1-16 http://informahealthcare.com/doi/pdf/10.1517/14740338.2015.1013532
World Health Organization (2014). Human papillomavirus vaccines: WHO position paper, Weekly epidemiological record position paper, No. 43, 89, 465-492 http://www.who.int/wer/2014/wer8943.pdf
Centers for Disease Control and Prevention (2014). Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007-2013, and Postlicensure Vaccine Safety Monitoring, 2006-2014 - United States. MMWR; 63 (29) 620-624 http://www.cdc.gov/mmwr/pdf/wk/mm6329.pdf
Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P and Hviid A (2013). Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 347:f5906 http://www.bmj.com/content/347/bmj.f5906
International Federation of Gynecology and Obstetrics FIGO (2013). Statement on HPV Vaccination Safety, August 2nd, 2013 http://www.figo.org/search?cx=%27006260962696807358306%3Ack4j2ap-l1u&cof=FORID%3A11&ie=ISO-8859-1&query=figo+statement+on+hpv+vaccines
World Health Organization (2013). Global Advisory Committee on Vaccine Safety. Update on human papillomavirus vaccines. Weekly Epidemiological Record 29 309-312 http://www.who.int/wer/2013/wer8829.pdf
Irish Medicines Board (2011). Overview of national monitoring experience with Gardasil. http://www.hpra.ie/docs/default-source/Safety-Notices/imb_gardasil_webupdate_19jul2011.pdf
Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J (2009). Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. Aug 19;302(7):750-7 http://jama.ama-assn.org/cgi/content/full/302/7/750
Please use the following links to access presentation slides from meetings held in May and August 2010 relating to HPV
Training slides from the HPV training programme held on the 6th May 2010.
Copy of Prof Margaret Stanleys presentation titled HPV VLP Vaccine Development and Impact. Prof Stanley spoke to an audience on the 31st August 2010.